Home › Funds › ARMISTICE CAPITAL, LLC › TVTX

ARMISTICE CAPITAL, LLC position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 500,000 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$28.4M, representing 0.37% of its reported portfolio and ranking #38 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed TVTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)500.00K sh
Reported value held$28.41M
Portfolio Weight0.37%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's TVTX position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in TVTX in Q3 2023 at 7,500,000 shares (US$67.0M). The position peaked in Q3 2025 at 6,724,000 shares, worth US$160.7M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 4 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 500,000 shares valued at US$28.4M — a reduction of -4,397,417 shares quarter over quarter.. Notable position changes include a 44% trim in Q4 2025 (shares fell 22% over the following quarter), a 30% increase in Q1 2026 (shares rose 91% over the following quarter), a 90% trim in Q2 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 7.50M $67.05M New
Q4 2023 7.38M $66.38M Reduce
Q1 2024 7.50M $57.83M Add
Q2 2024 7.50M $61.65M Hold
Q3 2024 7.65M $107.00M Add
Q4 2024 7.36M $128.18M Reduce
Q1 2025 8.87M $158.99M Add
Q2 2025 8.88M $131.36M Hold
Q3 2025 6.72M $160.70M Reduce
Q4 2025 3.76M $143.82M Reduce
Q1 2026 4.90M $145.50M Add
Q2 2026 500.00K $28.41M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held TVTX?

ARMISTICE CAPITAL, LLC has disclosed TVTX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in TVTX?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 500.00K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $28.41M, representing 0.37% of its reported portfolio and ranking #38.

Has ARMISTICE CAPITAL, LLC been buying or selling TVTX?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC reduced its position in TVTX. The position peaked in Q3 2025 at 6.72M shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.